Consecutive bestatin-hormone regimen induces redifferentiation of cancer cells in vitro.
When undifferentiated murine mammary adenocarcinoma cells were consecutively exposed to bestatin and estradiol or testosterone in vitro, morphological signs of redifferentiation of the cells were observed along with cellular enlargement and subsequent cell loss. These observations suggest that similar treatments can be applied clinically to cancers of the breast and prostate.
D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D012739:Gonadal Steroid Hormones / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D013739:Testosterone / Q000627:therapeutic use
D012739:Gonadal Steroid Hormones; D013739:Testosterone; D004958:Estradiol; D007930:Leucine; C012211:ubenimex